BCT score predicts chemotherapy benefit in Asian patients with hormone receptor-positive, HER2-negative, lymph node-negative breast cancer

The Breast Cancer Test (BCT) score has been validated for its ability to predict the risk of distant metastasis in hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer. This study aimed to examine the value of the BCT score for predicting the benefi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kwon, Mi Jeong, Lee, Sae Byul, Han, Jinil, Lee, Jeong Eon, Lee, Jong Won, Gong, Gyungyub, Beitsch, Peter D., Nam, Seok Jin, Ahn, Sei Hyun, Nam, Byung-Ho, Shin, Young Kee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6248959/
https://www.ncbi.nlm.nih.gov/pubmed/30462685
http://dx.doi.org/10.1371/journal.pone.0207155

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6248959/
https://www.ncbi.nlm.nih.gov/pubmed/30462685
http://dx.doi.org/10.1371/journal.pone.0207155

Ejemplares similares